The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Long glutamine tracts cause nuclear localization of a novel form of huntingtin in medium spiny striatal neurons in HdhQ92 and HdhQ111 knock-in mice
Abstract
Huntington's disease (HD) is caused by an expanded N-terminal glutamine tract that endows huntingtin with a striatal-selective structural property ultimately toxic to medium spiny neurons. In precise genetic models of juvenile HD, HdhQ92 and HdhQ111 knock-in mice, long polyglutamine segments change huntingtin's physical properties, producing HD-like in vivo correlates in the striatum, including nuclear localization of a version of the full-length protein predominant in medium spiny neurons, and subsequent formation of N-terminal inclusions and insoluble aggregate. These changes show glutamine length dependence and dominant inheritance with recruitment of wild-type protein, critical features of the altered HD property that strongly implicate them in the HD disease process and that suggest alternative pathogenic scenarios: the effect of the glutamine tract may act by altering interaction with a critical cellular constituent or by depleting a form of huntingtin essential to medium spiny striatal neurons.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
MACDONALD, M. (1993) · Cell · doi:10.1016/0092-8674(93)90585-e · Cited by 8,366
Mangiarini, L., Sathasivam, K., Seller, M., Cozens, B., Harper, A., Hetherington, C., Lawton, M., Trottier, Y., Lehrach, H., Davies, S. W., et al. (1996) · Cell · doi:10.1016/s0092-8674(00)81369-0 · Cited by 3,073
Aggregation of Huntingtin in Neuronal Intranuclear Inclusions and Dystrophic Neurites in Brain
DiFiglia, M., Sapp, E., Chase, K. O., Davies, S. W., Bates, G. P., Vonsattel, J. P., & Aronin, N. (1997) · Science · doi:10.1126/science.277.5334.1990 · Cited by 2,439
Davies, S. W., Turmaine, M., Cozens, B. A., DiFiglia, M., Sharp, A. H., Ross, C. A., Scherzinger, E., Wanker, E. E., Mangiarini, L., & Bates, G. P. (1997) · Cell · doi:10.1016/s0092-8674(00)80513-9 · Cited by 2,181
Zhuchenko, O., Bailey, J., Bonnen, P., Ashizawa, T., Stockton, D. W., Amos, C., Dobyns, W. B., Subramony, S. H., Zoghbi, H. Y., & Lee, C. C. (1997) · Nature Genetics · doi:10.1038/ng0197-62 · Cited by 1,583
Scherzinger, E., Lurz, R., Turmaine, M., Mangiarini, L., Hollenbach, B., Hasenbank, R., Bates, G. P., Davies, S. W., Lehrach, H., & Wanker, E. E. (1997) · Cell · doi:10.1016/s0092-8674(00)80514-0 · Cited by 1,291 · cited 1×
“An aggregation-promoting feature of polyglutamine is implicated by its ability to drive Nterminal fragments into SDS-insoluble aggregate in vitro (16) with glutamine-length dependence identical to the HD mechanism (17,18).”
BackgroundNuclear and Neuropil Aggregates in Huntington’s Disease: Relationship to Neuropathology
Gutekunst, C.-A., Li, S.-H., Yi, H., Mulroy, J. S., Kuemmerle, S., Jones, R., Rye, D., Ferrante, R. J., Hersch, S. M., & Li, X.-J. (1999) · The Journal of Neuroscience · doi:10.1523/jneurosci.19-07-02522.1999 · Cited by 914 · cited 3×
“Huntingtin antibody reagents were typically affinity purified: EM48 (amino acids 1–256) (21), HF1 (amino acids 1981–2580) (14), mAb HD549 (amino acids 549–679) (31), mAB2166 (amino acids 181–810) (Chemicon International, Temecula, CA) and mAb 1F8 glutamine segments >39 (14,17).”
BackgroundMethodSelf-citationActivation and Cleavage of Caspase-3 in Apoptosis Induced by Experimental Cerebral Ischemia
Namura, S., Zhu, J., Fink, K., Endres, M., Srinivasan, A., Tomaselli, K. J., Yuan, J., & Moskowitz, M. A. (1998) · The Journal of Neuroscience · doi:10.1523/jneurosci.18-10-03659.1998 · Cited by 893
Hodgson, J. G., Agopyan, N., Gutekunst, C.-A., Leavitt, B. R., LePiane, F., Singaraja, R., Smith, D. J., Bissada, N., McCutcheon, K., Nasir, J., et al. (1999) · Neuron · doi:10.1016/s0896-6273(00)80764-3 · Cited by 830
Schilling, G. (1999) · Human Molecular Genetics · doi:10.1093/hmg/8.3.397 · Cited by 753
Cited by
Cui, L., Jeong, H., Borovecki, F., Parkhurst, C. N., Tanese, N., & Krainc, D. (2006) · Cell · doi:10.1016/j.cell.2006.09.015 · Cited by 1,012
Molecular Mechanisms and Potential Therapeutical Targets in Huntington's Disease
Zuccato, C., Valenza, M., & Cattaneo, E. (2010) · Physiological Reviews · doi:10.1152/physrev.00041.2009 · Cited by 848
Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease
Slow, E. J. (2003) · Human Molecular Genetics · doi:10.1093/hmg/ddg169 · Cited by 800
Graham, R. K., Deng, Y., Slow, E. J., Haigh, B., Bissada, N., Lu, G., Pearson, J., Shehadeh, J., Bertram, L., Murphy, Z., et al. (2006) · Cell · doi:10.1016/j.cell.2006.04.026 · Cited by 651
Gray, M., Shirasaki, D. I., Cepeda, C., Andre, V. M., Wilburn, B., Lu, X.-H., Tao, J., Yamazaki, I., Li, S.-H., Sun, Y. E., et al. (2008) · Journal of Neuroscience · doi:10.1523/jneurosci.0857-08.2008 · Cited by 613
Dominant phenotypes produced by the HD mutation in STHdhQ111 striatal cells
Trettel, F. (2000) · Human Molecular Genetics · doi:10.1093/hmg/9.19.2799 · Cited by 610
Neurological abnormalities in a knock-in mouse model of Huntington's disease
Lin, C.-H. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.2.137 · Cited by 592
Dragatsis, I., Levine, M. S., & Zeitlin, S. (2000) · Nature Genetics · doi:10.1038/81593 · Cited by 576
Huntingtin–protein interactions and the pathogenesis of Huntington's disease
Li, S.-H., & Li, X.-J. (2004) · Trends in Genetics · doi:10.1016/j.tig.2004.01.008 · Cited by 548
Menalled, L. B., Sison, J. D., Dragatsis, I., Zeitlin, S., & Chesselet, M. (2003) · Journal of Comparative Neurology · doi:10.1002/cne.10776 · Cited by 536
Mutant huntingtin impairs axonal trafficking in mammalian neurons in vivo and in vitro
Trushina, E., Dyer, R. B., Badger, J. D., Ure, D., Eide, L., Tran, D. D., Vrieze, B. T., Legendre-Guillemin, V., McPherson, P. S., Mandavilli, B. S., et al. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.18.8195-8209.2004 · Cited by 520
“Studies of human brain (14), mouse models (48), and cells (8, 28) demonstrate that mutant huntingtin (mhtt) binds and sequesters its normal counterpart as well as many cellular proteins (41).”
BackgroundChoo, Y. S. (2004) · Human Molecular Genetics · doi:10.1093/hmg/ddh162 · Cited by 515
Ross, C. A. (2002) · Neuron · doi:10.1016/s0896-6273(02)00872-3 · Cited by 507
p53 Mediates Cellular Dysfunction and Behavioral Abnormalities in Huntington’s Disease
Bae, B.-I., Xu, H., Igarashi, S., Fujimuro, M., Agrawal, N., Taya, Y., Hayward, S. D., Moran, T. H., Montell, C., Ross, C. A., et al. (2005) · Neuron · doi:10.1016/j.neuron.2005.06.005 · Cited by 485
Menalled, L. B., Kudwa, A. E., Miller, S., Fitzpatrick, J., Watson-Johnson, J., Keating, N., Ruiz, M., Mushlin, R., Alosio, W., McConnell, K., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0049838 · Cited by 469
Lunkes, A., Lindenberg, K. S., Ben-Haı̈em, L., Weber, C., Devys, D., Landwehrmeyer, G. B., Mandel, J.-L., & Trottier, Y. (2002) · Molecular Cell · doi:10.1016/s1097-2765(02)00602-0 · Cited by 416
N-Methyl-d-aspartate (NMDA) receptor function and excitotoxicity in Huntington's disease
FAN, M., & RAYMOND, L. (2007) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2006.11.003 · Cited by 413
Molecular genetics: Unmasking polyglutamine triggers in neurodegenerative disease
Gusella, J. F., & MacDonald, M. E. (2000) · Nature Reviews Neuroscience · doi:10.1038/35039051 · Cited by 404
CRISPR/Cas9-mediated gene editing ameliorates neurotoxicity in mouse model of Huntington’s disease
Yang, S., Chang, R., Yang, H., Zhao, T., Hong, Y., Kong, H. E., Sun, X., Qin, Z., Jin, P., Li, S., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci92087 · Cited by 399
Transcriptional dysregulation in Huntington’s disease
Cha, J.-H. J. (2000) · Trends in Neurosciences · doi:10.1016/s0166-2236(00)01609-x · Cited by 397
Atwal, R. S., Xia, J., Pinchev, D., Taylor, J., Epand, R. M., & Truant, R. (2007) · Human Molecular Genetics · doi:10.1093/hmg/ddm217 · Cited by 387
Loss of normal huntingtin function: new developments in Huntington's disease research
Cattaneo, E. (2001) · Trends in Neurosciences · doi:10.1016/s0166-2236(00)01721-5 · Cited by 382
Kennedy, L. (2003) · Human Molecular Genetics · doi:10.1093/hmg/ddg352 · Cited by 380
Transgenic rat model of Huntington's disease
von Horsten, S. (2003) · Human Molecular Genetics · doi:10.1093/hmg/12.6.617 · Cited by 359
Li, H., Li, S.-H., Yu, Z.-X., Shelbourne, P., & Li, X.-J. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-21-08473.2001 · Cited by 359
Choosing an animal model for the study of Huntington's disease
Pouladi, M. A., Morton, A. J., & Hayden, M. R. (2013) · Nature Reviews Neuroscience · doi:10.1038/nrn3570 · Cited by 356
Rhes, a Striatal Specific Protein, Mediates Mutant-Huntingtin Cytotoxicity
Subramaniam, S., Sixt, K. M., Barrow, R., & Snyder, S. H. (2009) · Science · doi:10.1126/science.1172871 · Cited by 340
Interaction of Huntington Disease Protein with Transcriptional Activator Sp1
Li, S.-H., Cheng, A. L., Zhou, H., Lam, S., Rao, M., Li, H., & Li, X.-J. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.5.1277-1287.2002 · Cited by 340
Kuhn, A., Goldstein, D. R., Hodges, A., Strand, A. D., Sengstag, T., Kooperberg, C., Becanovic, K., Pouladi, M. A., Sathasivam, K., Cha, J.-H. J., et al. (2007) · Human Molecular Genetics · doi:10.1093/hmg/ddm133 · Cited by 328
Landles, C., Sathasivam, K., Weiss, A., Woodman, B., Moffitt, H., Finkbeiner, S., Sun, B., Gafni, J., Ellerby, L. M., Trottier, Y., et al. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.075028 · Cited by 326
Raymond, L. A., André, V. M., Cepeda, C., Gladding, C. M., Milnerwood, A. J., & Levine, M. S. (2011) · Neuroscience · doi:10.1016/j.neuroscience.2011.08.052 · Cited by 325
Systematic behavioral evaluation of Huntington's disease transgenic and knock-in mouse models
Menalled, L., El-Khodor, B. F., Patry, M., Suárez-Fariñas, M., Orenstein, S. J., Zahasky, B., Leahy, C., Wheeler, V., Yang, X. W., MacDonald, M., et al. (2009) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.05.007 · Cited by 324
Self-citationThe Neuropathology of Huntington’s Disease
Waldvogel, H. J., Kim, E. H., Tippett, L. J., Vonsattel, J.-P. G., & Faull, R. L. (2014) · Current Topics in Behavioral Neurosciences · doi:10.1007/7854_2014_354 · Cited by 317
Mouse models of Huntington's disease
Menalled, L. B., & Chesselet, M.-F. (2002) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(00)01884-8 · Cited by 315
Impaired Glutamate Uptake in the R6 Huntington's Disease Transgenic Mice
Liévens, J.-C., Woodman, B., Mahal, A., Spasic-Boscovic, O., Samuel, D., Kerkerian-Le Goff, L., & Bates, G. P. (2001) · Neurobiology of Disease · doi:10.1006/nbdi.2001.0430 · Cited by 313
The corticostriatal pathway in Huntington's disease
CEPEDA, C., WU, N., ANDRE, V, CUMMINGS, D., & LEVINE, M. (2007) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2006.11.001 · Cited by 310
Li, H., Li, S.-H., Johnston, H., Shelbourne, P. F., & Li, X.-J. (2000) · Nature Genetics · doi:10.1038/78054 · Cited by 303
Laforet, G. A., Sapp, E., Chase, K., McIntyre, C., Boyce, F. M., Campbell, M., Cadigan, B. A., Warzecki, L., Tagle, D. A., Reddy, P. H., et al. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-23-09112.2001 · Cited by 290
Vidal, R. L., Figueroa, A., Court, F. A., Thielen, P., Molina, C., Wirth, C., Caballero, B., Kiffin, R., Segura-Aguilar, J., Cuervo, A. M., et al. (2012) · Human Molecular Genetics · doi:10.1093/hmg/dds040 · Cited by 285
Lessons from animal models of Huntington's disease
Rubinsztein, D. C. (2002) · Trends in Genetics · doi:10.1016/s0168-9525(01)02625-7 · Cited by 283
Inhibition of Calpain Cleavage of Huntingtin Reduces Toxicity
Gafni, J., Hermel, E., Young, J. E., Wellington, C. L., Hayden, M. R., & Ellerby, L. M. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m401267200 · Cited by 281
Gines, S. (2003) · Human Molecular Genetics · doi:10.1093/hmg/ddg046 · Cited by 276
Pathogenic huntingtin inhibits fast axonal transport by activating JNK3 and phosphorylating kinesin
Morfini, G. A., You, Y.-M., Pollema, S. L., Kaminska, A., Liu, K., Yoshioka, K., Björkblom, B., Coffey, E. T., Bagnato, C., Han, D., et al. (2009) · Nature Neuroscience · doi:10.1038/nn.2346 · Cited by 275
Transcriptional signatures in Huntington's disease
Cha, J.-H. J. (2007) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2007.03.004 · Cited by 268
Mutant Huntingtin Causes Context-Dependent Neurodegeneration in Mice with Huntington's Disease
Yu, Z.-X., Li, S.-H., Evans, J., Pillarisetti, A., Li, H., & Li, X.-J. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-06-02193.2003 · Cited by 262
Genetics and Neuropathology of Huntington's Disease
Reiner, A., Dragatsis, I., & Dietrich, P. (2011) · International Review of Neurobiology · doi:10.1016/b978-0-12-381328-2.00014-6 · Cited by 261
Pinto, R. M., Dragileva, E., Kirby, A., Lloret, A., Lopez, E., St. Claire, J., Panigrahi, G. B., Hou, C., Holloway, K., Gillis, T., et al. (2013) · PLoS Genetics · doi:10.1371/journal.pgen.1003930 · Cited by 250
“which is both dominant and CAG length-dependent [16], is a”
BackgroundSelf-citationThe Energetics of Huntington's Disease
Browne, S. E., & Beal, M. F. (2004) · Neurochemical Research · doi:10.1023/b:nere.0000014824.04728.dd · Cited by 240
Huntingtin: an iron-regulated protein essential for normal nuclear and perinuclear organelles
Hilditch-Maguire, P. (2000) · Human Molecular Genetics · doi:10.1093/hmg/9.19.2789 · Cited by 226
Lynch, G., Kramar, E. A., Rex, C. S., Jia, Y., Chappas, D., Gall, C. M., & Simmons, D. A. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.5113-06.2007 · Cited by 181
“Hdh Q92 and Hdh Q111 mice have a chimeric mouse– human exon 1 with 92 and 111 repeats of the trinucleotide CAG, respectively (see next paragraph for actual CAG size determination), inserted into the huntingtin gene (Wheeler et al., 2000).”
BackgroundMitochondria and Huntington's Disease Pathogenesis: Insight from Genetic and Chemical Models
Browne, S. E. (2008) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1427.018 · Cited by 176
The pathogenic mechanisms of polyglutamine diseases and current therapeutic strategies
Bauer, P. O., & Nukina, N. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.06302.x · Cited by 178
Mielcarek, M., Landles, C., Weiss, A., Bradaia, A., Seredenina, T., Inuabasi, L., Osborne, G. F., Wadel, K., Touller, C., Butler, R., et al. (2013) · PLoS Biology · doi:10.1371/journal.pbio.1001717 · Cited by 172
Huntingtin-deficient zebrafish exhibit defects in iron utilization and development
Lumsden, A. L., Henshall, T. L., Dayan, S., Lardelli, M. T., & Richards, R. I. (2007) · Human Molecular Genetics · doi:10.1093/hmg/ddm138 · Cited by 156
Maiuri, T., Woloshansky, T., Xia, J., & Truant, R. (2013) · Human Molecular Genetics · doi:10.1093/hmg/dds554 · Cited by 128
(2018) · doi:10.1038/s41467-018-06675-3 · Cited by 111
Rivera, S., García-González, L., Khrestchatisky, M., & Baranger, K. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03178-2 · Cited by 111
Neuroinflammation in Huntington’s disease: From animal models to clinical therapeutics
Jia, Q., Li, S., Li, X.-J., & Yin, P. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1088124 · Cited by 70
“In HD KI mice expressing shorter CAG repeats (HdhQ92 or HTTQ111), no gliosis was found up to 17-18 months of age (55, 56).”
BackgroundSelf-citationMcClory, H., Williams, D., Sapp, E., Gatune, L. W., Wang, P., DiFiglia, M., & Li, X. (2014) · Acta Neuropathologica Communications · doi:10.1186/s40478-014-0178-7 · Cited by 60
“Immortalized striatal (STHdhQ7/Q7 and STHdhQ111/Q111) cells were obtained from Coriell and cultured as described [27].”
BackgroundMethodNeuroglia in neurodegeneration: Alzheimer, Parkinson, and Huntington disease
Lim, D., Matute, C., Cavaliere, F., & Verkhratsky, A. (2025) · Handbook of Clinical Neurology · doi:10.1016/b978-0-443-19102-2.00012-0 · Cited by 8
Metadata
- Authors
- Wheeler, V. C.
- Venue
- Human Molecular Genetics
- Publisher
- Oxford University Press (OUP)
- Published
- 2000-03-01
- Volume
- 9
- Issue
- 4
- Pages
- 503-513
- ISSN
- 0964-6906 (ISSN-L)
- 1460-2083
- OpenAlex
- W2168133967
- Cited by
- 469
- References
- 40
- FWCI
- 11.77
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.